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OBJECTIVES: To examine the cost-effectiveness of planned
caesarean section versus planned vaginal delivery in breech-
presentation pregnancies at term. METHODS: An incremental
cost-effectiveness analysis was performed using a Markov model
for a hypothetical cohort of 25-year old pregnant women with a
live singleton fetus in a frank or complete breech presentation
at term. Caesarean section was compared with vaginal delivery
from a societal perspective. The model operated over 25 years in
3-year cycles. The model integrated clinical and cost data from
peer-reviewed studies and utilities to estimate cumulative quality-
adjusted life years (QALYs) and costs for both the mother and
infant. Effects and costs were discounted at 4%. Probabilistic
sensitivity analyses were performed to determine key parameter
uncertainty. RESULTS: If only maternal morbidity was taken
into account, caesarean section was more costly and less effective
(incremental cost-effectiveness ratio (ICER) -€54,000 per
QALY), thus vaginal delivery was the dominated strategy. If only
neonatal morbidity and mortality was considered, caesarean
section was less costly and more effective (ICER -€2120 per
QALY). However, if outcomes for both mother and child were
considered, caesarean section was more costly but more effective
(ICER €1275 per QALY). CONCLUSIONS: Caesarean section
resulted to be cost-effective compared to vaginal delivery in
breech presentation at term, if both maternal and neonatal out-
comes were considered. If only maternal condition is considered,
vaginal delivery appeared to be the best strategy.
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OBJECTIVES: To compare the cost-effectiveness of different
therapies for the treatment of dysfunctional uterine bleeding
(DUB) in Spain. METHODS: A decision-analytic model was
built to estimate the clinical and economic consequences of ini-
tiating treatment for DUB with either levonorgestrel intrauterine
system (LNG-IUS), combined oral contraceptives (COC), pro-
gestogens (PROG) or tranexamic acid (TRAX) and switching to
COC (after failure with LNG-IUS or PROG) or to LNG-IUS
(after failure of COC) or to a combination of both (50% to
LNG-IUS and 50% to COC after failure with TRAX), whilst
surgery (hysterectomy and endometrial resection) was assumed
to be used as third line therapy in the base case. Model prob-
abilities were obtained from published systematic reviews and
treatment pathways after initial failure and/or presence of
adverse events (including pregnancy in women requiring contra-
ception) where derived from expert opinion. Local data on health
resources use and costs were used and validated by clinical
experts. Effectiveness was measured as symptom-free months
(SFM) and modelled up to 5 years. The analyses take the per-
spective of the National Health System, so excluding all costs not
supported by the public system (i.e. COC acquisition costs).
RESULTS: Preliminary results show that the higher efﬁcacy of
LNG-IUS translates to a gain of 0.3–3.42 SFM at 5 years. Whilst
LNG-IUS shows a short-term higher cost than the other options,
posterior savings derived from a lower surgery rate, due to a
better control of DUB, yields to cost savings respect to PROG,
COC and TRAX of €158.6, €179.6 and €270.7, respectively.
Furthermore, if surgery is assumed to be the only second line
option after ﬁrst line failures, cost savings with LNG-IUS could
be more than €400 after 5 years. CONCLUSIONS: Preliminary
results of this study indicate that LNG-IUS is a dominant option
with respect to COC, PROG or TRAX, with lower costs and
higher effectiveness than these therapies.
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Inﬂiximab has recently been approved for use in paediatric
patients with severe active Crohn’s disease (CD) and is the only
biologic licensed in this patient population. OBJECTIVES: To
estimate the cost effectiveness of scheduled maintenance treat-
ment with inﬂiximab among children suffering from severe
active CD in Scotland. METHODS: A Markov model was con-
structed to simulate the progression of a hypothetical cohort of
CD children through predeﬁned health states on scheduled
maintenance treatment with inﬂiximab (5 mg/kg) based on
Targan, ACCENT I and REACH trials. The health states used
in the model were remission, therapy (inﬂiximab) responsive
active disease, non-responsive active disease, surgery, post
surgery remission and post surgery complications. Standard
care, comprising immunomodulators and/or corticosteroids
was used as a comparator. The primary outcome was quality
adjusted life years (QALYs) estimated using EQ-5D from a
European CD population. An average patient weight of 40 kg
was used to estimate the dose of inﬂiximab. The costs and
outcomes were discounted at 3.5% over a period of 5 years.
Stochastic sensitivity analyses were performed by varying the
inﬂiximab efﬁcacy estimates, costs and utilities. RESULTS: The
incremental cost effectiveness ratio (ICER) for scheduled main-
tenance treatment with inﬂiximab was £12,483 for severe active
CD children in Scotland. The sensitivity analyses revealed the
analysis time horizon and efﬁcacy estimates to be the most inﬂu-
ential parameters with ICERs ranging from £5,348–£25,950.
CONCLUSIONS: Scheduled maintenance treatment with inﬂix-
imab (5 mg/kg) is a cost effective treatment option for children
suffering from severe active CD under an 8-week scheduled
maintenance programme in Scotland.
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OBJECTIVES: To summarise the existing evidence on the cost
of primary insomnia in persons aged 55 and above in Sweden
and to generate an estimate of its total societal cost based on
national statistics and other public sources. METHODS: We
performed a top-down cost of illness analysis based on the
Living Conditions Survey and national registry data from
the Swedish Social Insurance Board (Forsakringskassan), the
National Board of Health and Welfare (Socialstyrelsen) and the
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